Sample Page
Author:
X4 Pharmaceuticals
Posted Date:
May 6, 2026
X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
X4 Pharmaceuticals
May 6, 2026
X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union
X4 Pharmaceuticals
April 29, 2026
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
X4 Pharmaceuticals
April 1, 2026
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
X4 Pharmaceuticals
March 17, 2026
X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference
X4 Pharmaceuticals
March 4, 2026
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
X4 Pharmaceuticals
March 2, 2026
X4 Pharmaceuticals to Participate in Guggenheim’s Emerging Outlook: Biotech Summit 2026
X4 Pharmaceuticals
February 3, 2026
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
X4 Pharmaceuticals
February 2, 2026
